SERA
SERA
NASDAQ · Biotechnology

Sera Prognostics Inc-A

$1.72
-0.07 (-3.91%)
As of May 16, 9:41 PM ET ·
Financial Highlights (FY 2026)
Revenue
66.6K
Net Income
-26,232,430
Gross Margin
-102.5%
Profit Margin
-39,417.3%
Rev Growth
-33.1%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin -102.5% -102.5% 31.5% 31.5%
Operating Margin -45,066.7% -40,560.3% -8.6% -10.3%
Profit Margin -39,417.3% -37,446.4% -11.0% -9.9%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 66.6K 99.4K 14.53M 15.74M
Gross Profit -68,213 -101,901 4.57M 4.95M
Operating Income -30,000,431 -40,335,207 -1,252,159 -1,624,991
Net Income -26,232,430 -35,269,176 -1,603,701 -1,555,725
Gross Margin -102.5% -102.5% 31.5% 31.5%
Operating Margin -45,066.7% -40,560.3% -8.6% -10.3%
Profit Margin -39,417.3% -37,446.4% -11.0% -9.9%
Rev Growth -33.1% -33.1% +22.5% +19.6%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 26.23M 27.41M
Total Equity 39.07M 37.99M
D/E Ratio 0.67 0.72
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -29,220,241 -41,468,821 -1,702,906 -1,797,734
Free Cash Flow -884,905 -1,153,129